Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Erlotinib + Fluorouracil + Vemurafenib |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colon cancer | sensitive | Erlotinib + Fluorouracil + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Adrucil (fluorouracil) to treatment with the combination of Tarceva (erlotinib) and Zelboraf (vemurafenib) resulted in greater inhibition of viability of mouse colon cancer organoids harboring BRAF V600E in culture compared to Adrucil (fluorouracil) or the doublet combination therapy (PMID: 39626159). | 39626159 |
PubMed Id | Reference Title | Details |
---|---|---|
(39626159) | Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer. | Full reference... |